← FDA DRUG APPROVALS

FDA ANDA · ANDA076221

JINTELI

norethindrone acetate and ethinyl estradiol

Sponsor: BARR LABS INC

APPLICATION
ANDA076221
TYPE
ANDA
ORIGINAL APPROVAL
2009-11-06
LATEST ACTION
2024-02-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOLPrescription
ETHINYL ESTRADIOL 0.005MG, NORETHINDRONE ACETATE 1MG · TABLET · ORAL

Approval history

2024-02-15Labeling · Supplement 15 · standardAP
2024-01-29Labeling · Supplement 14 · standardAP
2015-01-07Labeling · Supplement 8 · standardAP
2009-11-06OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →